CSF3 and type 1 diabetes mellitus: A single-blinded randomized placebo-controlled study demonstrated a preservation of C-peptide in patients with established T1D, through the combination of anti-thymocyte globulin (ATG) and pegylated G-CSF for 12 months following treatment.